Related Experiment Video
Updated: Aug 14, 2026
10:37
Induction and Analysis of Epithelial to Mesenchymal Transition
Published on: August 27, 2013
Identifying Epithelial-Cell Progression Signatures (ECPSs) from Multi-Resolution Multi-Omics Data for Translational
Xueyao Chen1, Tongxin Lv1, Yang Wu1
1College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
International Journal of Molecular Sciences
|August 13, 2026
Summary
Researchers identified two key gene expression signatures in lung adenocarcinoma (LUAD): a Cancer-Promoting Signature (CPS) and a Cancer-Suppressing Signature (CSS). These signatures show promise as diagnostic and prognostic biomarkers for LUAD and other cancers.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Dynamic transcriptomic changes in epithelial cells are crucial for lung adenocarcinoma (LUAD) progression.
- Epithelial-cell progression signatures (ECPSs) driving LUAD transformation are not fully understood.
Purpose of the Study:
- To identify and characterize ECPSs involved in LUAD progression.
- To evaluate the diagnostic and prognostic potential of identified signatures.
Main Methods:
- Multi-resolution, multi-omics analysis of LUAD tissues.
- Validation of signatures using independent transcriptomic datasets.
- Assessment of diagnostic accuracy (AUC) and prognostic value in patient cohorts.
Main Results:
- Identified two opposing ECPSs: Cancer-Promoting Signature (CPS) and Cancer-Suppressing Signature (CSS).
- CPS is upregulated, while CSS is downregulated during LUAD progression, with high diagnostic accuracy (>0.95 AUC).
- CPS and CSS predict prognosis, stratify patients, and correlate with genomic instability and immune microenvironment.
Conclusions:
- CPS and CSS are clinically relevant ECPSs with significant diagnostic and prognostic value for LUAD.
- These signatures may serve as biomarkers for early detection and personalized treatment strategies.
- The identified signatures demonstrate translational potential across various epithelium-derived cancers.
